Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03569241
Other study ID # EC/2018/0130
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date April 27, 2018
Est. completion date April 30, 2025

Study information

Verified date June 2023
Source University Hospital, Ghent
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A proportion of prostate cancer (PCa) patients develop relapse following curative local treatment. Regional nodal recurrence is an emerging clinical situation since the introduction of new molecular imaging methods in the restaging of recurrent prostate cancer. More specifically, a subgroup of these patients is being diagnosed with a recurrence confined to the regional lymph nodes and limited in number (oligorecurrence) using choline or PSMA PET-CT. As there are no specific treatment recommendations for these type of patients, different treatment approaches are currently used, mostly focusing on local ablative treatments using radiotherapy or surgery. These treatments are coined metastasisdirected therapy (MDT). MDT in combination with or without temporary ADT could delay the subsequent risk of progression, and even cure limited regional nodal recurrences. Consequently, lifelong palliative ADT, with its toxicity and excess in non-cancer mortality might be postponed. The proposed trial randomizes patients with oligorecurrent nodal prostate cancer following primary PCa treatment to either metastasis-directed therapy (MDT) (salvage lymph node dissection, sLND or stereotactic body radiotherapy, SBRT) or MDT plus whole pelvis radiotherapy (WPRT: 45 Gy in 25 fractions).


Description:

A proportion of prostate cancer (PCa) patients develop a local, regional (N1) or distant (M1) relapse following curative local treatment. For both local and distant relapses, different treatment recommendations are made in the guidelines (EAU guidelines 2016). However, the entity regional nodal recurrence is not mentioned in the guidelines but is an emerging clinical situation since the introduction of choline and more recently PSMA PET-CT in the restaging of recurrent prostate cancer. More specifically, a subgroup of these patients is being diagnosed with a recurrence confined to the regional lymph nodes and limited in number (oligorecurrence) using choline or PSMA PET-CT. As there are no specific treatment recommendations for these type of patients, different treatment approaches are currently used, mostly focusing on local ablative treatments using radiotherapy or surgery. These treatments are coined metastasisdirected therapy (MDT). MDT in combination with or without temporary ADT could delay the subsequent risk of metastases, and even cure limited regional nodal recurrences. Consequently, lifelong palliative ADT, with its toxicity and excess in non-cancer mortality might be postponed. The proposed trial randomizes patients with oligorecurrent nodal prostate cancer following primary PCa treatment to either metastasis-directed therapy (MDT) (sLND or SBRT) or MDT plus WPRT. In the recurrent PCa setting, 2 recent trials have suggested a progression-free and even survival benefit of adding temporary ADT to local salvage prostate bed radiotherapy. Consequently, this positive effect might also be applicable for regional recurrences. Although the optimal duration of ADT is unknown, a minimal duration of 6 months of ADT seems advisable in this setting and will be mandatory for both arms. This trial will improve our insights in the pattern of recurrence following these treatment modalities with the expectation that WPRT will reduce the number of nodal relapses, improving metastasis-free survival and postponing the need for palliative systemic treatments while maintaining quality-of-life. The current phase II trial will try to establish a golden standard in the treatment of oligorecurrent nodal PCa.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 196
Est. completion date April 30, 2025
Est. primary completion date April 30, 2023
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically proven initial diagnosis of adenocarcinoma of the prostate - Biochemical relapse of prostate cancer following radical local prostate treatment (radical prostatectomy, primary radiotherapy or radical prostatectomy +/- prostate bed adjuvant/ salvage radiotherapy) according to the EAU guidelines 2016. - Following radical prostatectomy, patients with a biochemical relapse are eligible in case a nodal relapse is detected in the pelvis even in the absence of prior postoperative prostate bed radiotherapy (adjuvant or salvage). - In case of a suspected local recurrence following primary radiotherapy, a biopsy should confirm local recurrence and patients with a confirmed local recurrence are eligible in case they also undergo a local salvage therapy. If imaging rules out local relapse, patients are eligible. - Nodal relapse in the pelvis on choline, PSMA or FACBC PET-CT with a maximum of 3 positive nodal lymph nodes. The upper limit of the pelvis is defined as the aortic bifurcation. - WHO performance state 0-1 - Age >18 years - Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial - Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations. Exclusion Criteria: - Bone or visceral metastases - Para-aortic lymph node metastases (above the aortic bifurcation) - Local relapse in the prostate gland or prostate bed not suitable for a curative treatment - Previous irradiation of the pelvic and or para-aortic nodes - Serum testosterone level <50ng/dl or 1.7 nmol/L at time of randomization - Symptomatic metastases - Lymph node metastases in previously irradiated areas resulting in dose constraint violation - Contraindications to pelvic radiotherapy (chronic pelvic inflammatory bowel disease) - Contraindications to androgen deprivation therapy - PSA rise while on active treatment with (LHRH-agonist, LHRH-antagonist, anti-androgen, estrogen - Previous treatment with cytotoxic agent for PCa - Treatment during the past month with products known to influence PSA levels (e.g. fluconazole, finasteride, corticosteroids,…) - Other active malignancy, except non-melanoma skin cancer or other malignancies with a documented disease-free survival for a minimum of 3 years before randomization.

Study Design


Intervention

Radiation:
whole pelvic radiotherapy
addition of prophylactic whole pelvic radiotherapy to a local metastasis-directed treatment
metastasis-directed treatment
stereotactic body radiotherapy
Procedure:
salvage Lymph Node Dissection
metastasis-directed treatment
Drug:
androgen deprivation therapy
LHRH-agonist (+ anti-androgen) or antagonist for a duration of 6 months

Locations

Country Name City State
Australia Epworth Healthcare Melbourne
Belgium GZA Antwerp
Belgium AZ St-Jan Brugge Brugge
Belgium AZ St-Lucas Brugge
Belgium Institut Jules Bordet Brussel
Belgium AZ Maria Middelares Gent
Belgium University Hospital Ghent Ghent
Belgium AZ Groeninge Kortrijk
Belgium UZ Leuven Leuven
Belgium CH Mouscron Mouscron
Italy Humanitas Research Hospital Milan
Italy Vita-Salute San Raffaele University Milan
Italy Istituto Nazionale Tumori IRCCS Napoli
Italy Fondazione IRCCS Policlinico S. Matteo Pavia
Italy Ospedale Sacro Cuore-Don Calabria Verona
Norway Oslo University Hospital Oslo
Spain Cruces University Hospital Barakaldo
Spain Clínica Universitaria IMQ Bilbao
Spain Hospital Ramón y Cajal Madrid
Spain Hospital Universitario La Princesa Madrid
Spain Universitario Quironsalud Madrid
Spain Hospitalario de Navarra Navarro
Spain Hospital Clínico de Santiago Santiago
Spain Hospital Universitari i Politècnic la Fe Valencia
Switzerland Universitätsspital Basel Basel
Switzerland Universitätsklinik für Radio-Onkologie Bern
Switzerland Hôpitaux Universitaires de Genève Geneva
Switzerland Kantonsspital St. Gallen Saint Gallen
Switzerland UniversitätsSpital Zürich Zürich

Sponsors (2)

Lead Sponsor Collaborator
University Ghent University Hospital, Geneva

Countries where clinical trial is conducted

Australia,  Belgium,  Italy,  Norway,  Spain,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Metastases-free survival Metastasis-free survival will be defined as the time between randomization and the appearance of a metastatic recurrence (any M1) as suggested by choline, FACBC or PSMA PET-CT or death due to any cause 2 year
Secondary Clinical Progression free survival Clinical Progression-free survival is defined as time between randomization and the appearance of a new recurrence (any N1 or M1) as suggested by PET-CT, symptoms related to progressive PCa, or death due to any cause 2 year
Secondary Biochemical progression-free survival For patients who had previous RP at initial diagnosis, a biochemical recurrence is defined by any confirmed PSA rise above 0.20 ng/ml with a confirmatory rise at least 2 weeks later. For patients who had previous RT to the prostate at initial diagnosis, a biochemical recurrence is defined as the nadir + 2ng/ml (Phoenix definition). Non-responders are considered to have a biochemical recurrence in case a second measurement at least 2 weeks later confirms a rising PSA 2 year
Secondary Toxicity: acute toxicity Radiotherapy toxicity will be assessed according to NCI CTCAE v4.0. 3 months
Secondary Toxicity: late toxicity Radiotherapy toxicity will be assessed according to NCI CTCAE v4.0. 2 year
Secondary Patient reported QOL as per EORTC-QLQ C30 Validated questionnaire assessing different health-related parameters (psychological, physical and social well-being) in cancer patients 2 year
Secondary Patient reported QOL as per EORTC-QLQ PR25 Validated questionnaire assessing the health-related QOL of prostate cancer patients 2 year
Secondary Prostate cancer-specific survival Cancer specific survival will be read as the time from trial randomization to the date of death due to prostate cancer 5 year
Secondary Overall survival Overall survival will be read as the time from trial randomization to the date of death from any cause 5 year
Secondary Time to start of hormonal treatment Time to hormonal treatment is defined as the time from trial randomization to start of hormonal treatment 2 year
Secondary Time to castration-resistant disease Time to castration resistant disease is defined as the time from trial randomization until castration resistant status 5 year
Secondary economical evaluation Assessment of quality-adjusted-life-years with the EuroQol classification system (EQ-5D-5L) 2 year
Secondary Sensitivity/specificity of PET-CT for the detection of nodal recurrences: limited to patients undergoing surgery Sensitivity/specificity of PET-CT 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A